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Purpose: Radiotherapy plan evaluation is currently performed by assessing physical 
parameters, which has many limitations. Biological modelling can potentially allow plan 
evaluation that is more reflective of clinical outcomes, however further research is required 
into this field before it can be used clinically. 
Methods: A simple program, RADBIOMOD, has been developed using Visual Basic for 
Applications (VBA) for Microsoft Excel that incorporates multiple different biological 
models for radiotherapy plan evaluation, including modified Poisson tumour control 
probability (TCP), modified Zaider-Minerbo TCP, Lyman-Kutcher-Burman normal tissue 
complication probability (NTCP), equivalent uniform dose (EUD), EUD-based TCP, EUD-
based NTCP, and uncomplicated tumour control probability (UTCP). RADBIOMOD was 
compared to existing biological modelling calculators for 15 sample cases. 
Results: Comparing RADBIOMOD to the existing biological modelling calculators, all 
models tested had mean absolute errors and root mean square errors less than 1%. 
Conclusions: RADBIOMOD produces results that are non-significantly different from 
existing biological modelling calculators for the models tested. It is hoped that this freely 
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Radiotherapy plan evaluation is an essential part of the radiotherapy treatment workflow [1]. 
Multiple different plans can be created for individual patients that have different 
compromises between doses to target volumes and normal tissues. The goal of radiotherapy 
plan evaluation is to select the plan that has the best therapeutic ratio (high tumour control 
probability (TCP) and low normal tissue complication probability (NTCP)). 
 
The current standard for evaluating radiotherapy treatment plans is the assessment of physical 
parameters such as dose-volume constraints on the dose-volume histogram (DVH). These 
parameters are used as surrogates for TCP and NTCP. The TCP is thought to be maximal if 
the dose-volume constraints are met for the target volume, and the NTCP is thought to be 
minimal if the constraints are met for the normal tissue. For example, tumour control for 
certain head and neck cancers may be thought to be likely if the D95 for the planning target 
volume (PTV) is above 70 Gy, and radiation myelopathy thought to be unlikely to occur if 
the maximum dose is below 45 Gy [2]. This sole assessment of physical parameters is a very 
simplistic way of evaluating the adequacy of radiotherapy treatment plans, and as such, has a 
number of limitations. 
 
Firstly, these constraints suggest a binary outcome – of an effect occurring or not occurring 
based on whether or not the constraint is achieved – when in reality the probabilities of these 
outcomes are continuous [3]. Secondly, a number of different DVH curves may pass through 
the same points, but be of markedly different shapes (e.g. curved versus step-wise) and 
therefore likely to be associated with different outcomes [2]. Thirdly, there are usually 
multiple constraints that are defined as goals for each target volume and normal tissue, and 
often not all of them can be achieved simultaneously. In these situations, it is difficult to 
assess which would be the optimal plan to use. 
 
Biological modelling has been proposed as a way of overcoming some of these limitations. 
Based on our knowledge of radiobiology, which has increased markedly over the last few 
decades, mathematical models have been proposed that provide metrics for estimating TCP 
and NTCP that may be superior to physical parameters. For example, instead of evaluating 
multiple physical parameters for each target volume and normal tissue, a single TCP 
parameter and a single NTCP parameter for each normal tissue can be evaluated. Potentially, 
the TCP and each NTCP can be simplified even further as a single uncomplicated tumour 
control probability (UTCP) metric, which can be used to rank plans [3]. 
 
While biological modelling has a lot of promise, it is still an investigational tool. There is not 
enough evidence yet of its predictive power to use it in routine clinical practice. Multiple 
reports and statements have called for more research to be made into this field so that it may 
one day be used in routine clinical practice [2-4]. However, research into this field is 
currently hampered by the complexity and inaccessibility of currently available biological 
modelling programs. 
 
We have developed a simple program, RADBIOMOD, which is user-friendly and would be 
easily accessible for any radiation oncologist, radiation therapist, or physicist for biological 
plan evaluation. It provides a common platform that is not specific to any particular treatment 
planning system (TPS). It is hoped that by providing a user-friendly program on a common 
platform, more research can be made into this topic such that we may bring this closer to 







Visual Basic for Applications (VBA) for Microsoft Excel was chosen as the programming 
language of choice to implement the biological models. This was chosen because Microsoft 
Excel is already readily available in most radiotherapy departments, and its basic functions 
should already be familiar to most radiation oncologists, radiation therapists, and medical 
physicists. Furthermore, the VBA code can be easily edited if the user requires the models to 
be customised. 
 
RADBIOMOD requires the user to input the DVH data for the target volume or normal tissue 
of interest in tabular format, with dose in the first column and volume in the second column. 
The default DVH format that RADBIOMOD uses for calculation is differential. 
RADBIOMOD can also convert cumulative DVHs into differential if required. The default 
units are dose in Gy and volume in percentage; however other units can be easily converted 
or customised in RADBIOMOD. Most commercial treatment planning systems (TPS) can 
export the DVH in comma-separated value (CSV) or similar format, which can be copied and 
pasted into RADBIOMOD. 
 
Several TCP, NTCP, equivalent uniform dose (EUD) and UTCP models were chosen for 
inclusion into RADBIOMOD. The mathematical equations describing each model are briefly 
described below. Readers are referred to the original papers for details and derivation of the 




Modified Poisson (MP) TCP model 
 
A model for TCP derived using Poisson statistics and the linear quadratic (LQ) model has 
previously been described [5, 6]. This is known as the Poisson model because it assumes that 
the number of surviving clonogens is Poisson-distributed. This model calculates the 
probability of there being no viable clonogens left in the tumour after a course of 
radiotherapy. 
 
In its simplest form, the number of surviving clonogens after a course of fractionated external 
beam radiotherapy can be described as: 
 
𝑁𝑆 = 𝑁0 [exp(−𝛼𝑑 − 𝛽𝑑
2)]𝑁 = 𝑁0exp (−𝛼𝐷 − 𝛽𝐷𝑑))     (1) 
 
where NS is the number of surviving clonogens, N0 is the initial number of clonogens,  and  
are LQ radiosensitivity parameters, with total dose D given homogeneously to the target over 
N fractions, each one of dose d. The TCP can then be estimated using Poisson statistics as 
 
𝑇𝐶𝑃 = exp(−𝑁𝑆) = exp (−𝑁0exp [−𝛼𝐷 − 𝛽𝐷𝑑])      (2) 
 The N0 parameter can also be expressed as ρ, the clonogenic cell density in the target volume 
multiplied by the total volume of the target volume. Considering the case of heterogeneous 
dose distributions, we can assume the tumour volume to be composed of a series of 
subvolumes, vi, each receiving a homogeneous dose di. 
 
𝑇𝐶𝑃 = ∏ exp ( −𝜌𝑣𝑖 exp (−𝛼𝐷𝑖 (1 +
𝛽
𝛼
𝑑𝑖)))𝑖       (3) 
 
The population variability in radiosensitivity can also be incorporated into this model. This is 









2 )        (4) 
 
𝑇𝐶𝑃 = ∑ 𝑔𝑗(𝜎𝛼)𝑗 ∏ exp [ −𝜌𝑣𝑖 exp (−𝛼𝑗𝐷𝑖 (1 +
𝛽
𝛼
𝑑𝑖))]𝑖      (5) 
 
There have been many modifications to the Poisson TCP model. We chose a model that 
incorporates several additional radiobiological factors including hypoxia, radiosensitisation, 
and repopulation [7] 
 
𝑇𝐶𝑃 = ∑ 𝑔𝑗(𝜎𝛼)𝑗 ∏ exp [ −𝜌𝑣𝑖 exp (−𝛼𝑗𝐷𝑖 ∙ 𝑆𝐸𝑅 (1 +
𝛽
𝛼
𝑑𝑖 ∙ 𝑆𝐸𝑅) +
ln (2)
𝑇𝑝𝑜𝑡
(𝑇 − 𝑇𝑘))]𝑖  (6) 
 
where SER is the sensitiser enhancement ratio, T is the overall treatment time, Tk is the kick-
off time, and Tpot is the potential doubling time. 
 LQ radiosensitivity parameters for hypoxic (H) and aerobic (A) cells can be determined 




𝑂𝐸𝑅⁄           (7) 
(𝛼 𝛽⁄ )
𝐻
= (𝛼 𝛽⁄ )
𝐴
∙ 𝑂𝐸𝑅         (8) 
where OER is the oxygen enhancement ratio. 
 
The overall TCP can be calculated based on dividing the cells into a hypoxic fraction (HF) 
and an aerobic fraction (1 – HF), and then calculating the TCP for each group, using the 
hypoxia-modified radiosensitivity parameters described in equations (7) and (8) [7]: 
 
𝑇𝐶𝑃 = 𝑇𝐶𝑃𝐻(𝐻𝐹) + 𝑇𝐶𝑃𝐴(1 − 𝐻𝐹)       (9) 
The above equation does not distinguish between the differing doses received by hypoxic and 
non-hypoxic regions. This should be used when the geographic location of hypoxia is 
unknown. When hypoxia imaging (for example, 18F-fluoromisonidazole PET) is performed, 
and the geographic location of hypoxia is known, the gross tumour volume (GTV) should be 
split into a hypoxic GTV (GTVH) (as defined by the hypoxia imaging) and a non-hypoxic 
GTV (GTVA) (derived by performing a Boolean subtraction of GTVH from GTV on the TPS). 
The overall TCP can then be calculated by finding the product of the TCPs for each volume: 
 
𝑇𝐶𝑃 = 𝑇𝐶𝑃𝐻(𝐺𝑇𝑉𝐻) ∙ 𝑇𝐶𝑃𝐴(𝐺𝑇𝑉𝐴)        (10) 
 
The main limitation of the Poisson TCP model is that the TCP for protracted treatments has 
been shown to be non-Poissonian because of cell proliferation between fractions [9]. 
However, other studies have shown that in the condition of a small surviving fraction and a 
large number of clonogens, the distribution does still converge to the Poisson distribution, 
and as such the Poisson models do still fit reasonably well to experimental data [9]. 
 
Modified Zaider-Minerbo (MZM) TCP model 
 
A model for TCP derived using the theory of birth-and-death stochastic processes was 
originally described by Zaider and Minerbo [10]. The mathematics behind this model is 
thought to be more accurate than the Poisson models [9]. This was later adapted for the case 
of fractionated delivery with varying time intervals between fractions and heterogeneous dose 
distributions [11, 12]. We have incorporated the concept of kick-off time into this model: 
 
𝑇𝐶𝑃 = ∏ 𝑇𝐶𝑃(𝐷𝑖, 𝑣𝑖)𝑖          (11) 
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where n is the number of fractions, λ is the rate of cellular repopulation, Tj is the time 
between the jth fraction and the first fraction, Tk is the kick-off time, t(Tj) is the number of 
days Tj is beyond Tk, and ρ is the clonogenic cell density. ps(Tj) is the cell survival after the 
jth fraction, as predicted using the linear-quadratic model, where  and  are radiosensitivity 
parameters, and Di is the total dose delivered to a subvolume, vi. 
 
The MZM model is relatively simplistic and does not take important radiobiological factors 
such as hypoxia and cell cycle effects into consideration. However, this model can easily be 




Lyman-Kutcher-Burman (LKB) NTCP model 
 
Emami et al. published a seminal paper in 1991 [13], describing the tolerance dose values for 
28 critical structures, which provided the framework for much of the modern research into 
normal tissue tolerances. Burman [14] fit the tolerance dose data from that paper into a 
phenomenological NTCP model proposed by Lyman [15]. Kutcher and Burman [16] later 
developed a method for DVH reduction that could take heterogeneous dose distributions into 
account. The combined formalism is often referred to as the LKB model. A mathematically 
equivalent but clearer formulation of the LKB model has been proposed [17-19], consisting 
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where Deff is the dose that, if given uniformly to the entire volume, will lead to the same 
NTCP as the actual non-uniform dose distribution, and Di is the dose given to a subvolume, vi. 
This model has three parameters: n, m and TD50. The volume dependence of the complication 
probability is given by n and the slope of the complication probability vs dose curve is given 
by m. TD50 is the dose to the whole organ that would lead to a complication probability of 
50%. 
 
Biological dose adjustment is sometimes considered in the LKB model. This is an important 
consideration because dose heterogeneity in normal tissues will have biological effects due to 
the varying fraction sizes as well as total dose. [6] Furthermore, where fraction sizes other 
than 2 Gy per fraction are used, the unadjusted “physical” DVH may not be reflective of 
biological effect. This can be accounted for by calculating the equivalent dose in 2 Gy per 
fraction (EQD2) for each dose bin as follows: 





          (18) 
 
where Di is the total dose received by the dose bin and di is the dose-per-fraction received by 
the dose bin. This adjusted DVH can then be applied to the LKB equations as described 
above. 
 
By default, all of the parameters listed in Table 1 are available for the user to select in 
RADBIOMOD. The user is free to edit these values or enter completely new ones to be saved 
in RADBIOMOD. 
 
There are two main limitations of the LKB model. Firstly, not all of the parameters have been 
updated, and as such, many of them are still based on Emami estimates [13], the accuracy of 
which have been criticised [20]. Secondly, the method of DVH reduction employed can result 






The EUD is defined as the biologically equivalent dose that if given uniformly, will lead to 
the same biological effect as the actual nonuniform dose distribution [21]. It can be applied to 
both tumours and normal tissues. It is described by the following formula [22]: 
 




𝑎          (19) 
 
where the dose, Di is delivered to a subvolume, vi, and a is a unitless model parameter that is 
specific to the normal structure or tumour of interest. 
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where the TCD50 is the tumour dose required to control 50% of the tumours when the tumour 
is homogeneously irradiated, the TD50 is the normal tissue dose that would lead to a 
complication probability of 50% if the normal tissue is homogeneously irradiated, and the 50 
is a unitless model parameter that is specific to the normal tissue or tumour of interest and 




The UTCP is the probability of controlling a tumour without causing normal tissue 
complications. In its simplest form, it is given using the following formula: 
 
𝑈𝑇𝐶𝑃 = 𝑇𝐶𝑃 ∙ (1 − 𝑁𝑇𝐶𝑃)         (22) 
 
defined using the TCP for a tumour and the NTCP for a single nearby organ. 
 
This was modified by Agren et al. [23] to include a correlation parameter, δ to describe the 
fraction of patients where tumour control and normal tissue complications are statistically 
independent and where multiple normal tissues can be accounted for using the following 
formulae: 
 𝑈𝑇𝐶𝑃 = 𝑇𝐶𝑃 − 𝑃𝐼 + 𝛿𝑃𝐼(1 − 𝑇𝐶𝑃)        (23) 
 
𝑃𝐼 = 1 − ∏ (1 − 𝑁𝑇𝐶𝑃𝑖)𝑖=1          (24) 
 
where PI is the probability of injury to each normal tissue of interest, i. 
 
The UTCP model makes the assumption that gains in TCP are of equal value to drops in 
NTCP without consideration of the clinical importance of the endpoints that are being 
estimated. Clearly, a small gain in TCP would not offset a small rise in the risk of an 
unacceptable toxicity such as myelopathy. Furthermore, if there are errors in the underlying 
TCP or NTCP functions, the UTCP would also be inaccurate [24]. As such, until these 
models are improved, clinical judgement must still be used rather than relying purely on this 
metric to rank the plans. 
 
Validation of calculations 
 
The accuracy of the biological modelling calculations in RADBIOMOD were validated by 
comparing them to the same calculations performed on other biological modelling programs 
using sample clinical cases.  
 
The biological modelling programs selected for comparison include XiO 4.70 (Elekta, 
Stockholm, Sweden), CERR [25], EUDMODEL [22], and TCP_NTCP_CALC [12]. XiO was 
selected because its biological models (MP TCP and LKB NTCP) are well described, the 
models are similar to those used in RADBIOMOD, and is widely used as a clinical TPS. 
CERR was chosen because it has the ability to calculate LKB NTCP using similar 
calculations as in RADBIOMOD, and is freely available. EUDMODEL and 
TCP_NTCP_CALC were chosen because they were created by the authors of the EUD 
TCP/NTCP and MZM TCP models, respectively and to our knowledge are the only available 
calculators for these models.  
 
15 sample cases were randomly selected from recently treated clinical cases in our 
department. These patients consisted of five patients with head and neck malignancies, 
treated with curative-intent radiotherapy to 70 Gy in 35 fractions using IMRT techniques; 
five patients with prostate cancer, treated with curative-intent radiotherapy to 78 Gy in 39 
fractions using IMRT techniques; and five patients with lung cancer, treated with curative-
intent radiotherapy to a dose of 60 Gy in 30 fractions using 3D-conformal techniques. 
 
MP TCP was calculated on RADBIOMOD and XiO for five head and neck cancer patients 
and five prostate cancer patients. The following parameters were used for head and neck 
cancer: α = 0.40 Gy-1, σα= 0.07 Gy-1, clonogenic cell density = 107 clonogens/cm3, kick-off 
time (Tk) = 28 days, potential doubling time (Tpot) = 3 days [7]. The following parameters 
were used for prostate cancer: α = 0.26 Gy-1, σα= 0.06 Gy-1, clonogenic cell density = 106 
clonogens/cm3 [26], no kick-off time, and potential doubling time (Tpot) = 42 days [27]. The 
 term was not used in these calculations, as it is not available in XiO due to the assumption 
that its effects are minimal where 2 Gy per fraction is used and the tumour has a high / 
ratio. 
 
MZM TCP was calculated on RADBIOMOD and TCP_NTCP_CALC for five head and neck 
cancer patients and five prostate cancer patients. The following parameters were used for 
head and neck cancer: α = 0.396 Gy-1,  = 0.0396 Gy-2, clonogenic cell density = 107 
clonogens/cm3, and λ = 0.231 [7]. The following parameters were used for prostate cancer: α 
= 0.26 Gy-1,  = 0.0312 Gy-2, clonogenic cell density = 106 clonogens/cm3 [26], and λ = 
0.0165 [27]. The kick-off time was not used in these calculations. 
 
LKB NTCP was calculated on RADBIOMOD, XiO, and CERR for the parotids for five head 
and neck cancer patients and for the lungs for five lung cancer patients. The following 
parameters were used for the parotids: TD50 = 31.4 Gy, n = 1, m = 0.53 [19]. The following 
parameters were used for the lungs: TD50 = 31.4 Gy, n = 1, m = 0.45 [2]. Corrections for 
dose-per-fraction were not used as this feature is not available in XiO or CERR. 
 
EUD TCP was calculated on RADBIOMOD and EUDMODEL for five head and neck cancer 
patients and five prostate cancer patients. The following parameters were used for head and 
neck cancer: TCD50 = 64.9 Gy, 50 = 3.2, and a = -13 [22, 28, 29]. The following parameters 
were used for prostate cancer: TCD50 = 70.5, 50 = 2.9, and a = -24 [30, 31]. 
 
EUD NTCP was calculated on RADBIOMOD and EUDMODEL for the parotids for five 
head and neck cancer patients and for the lungs for five lung cancer patients. The following 
parameters were used for the parotids: TD50 = 31.4, a = 1, 50 = 2 [19, 22]. The following 
parameters were used for the lungs: TD50 = 31.4, a = 1, 50 = 2 [2, 22]. 
 
Ethical approval and statistical analyses 
 
The Austin Health Human Research Ethics Committee granted approval for this study. The 
biological modelling calculation results with RADBIOMOD were compared with those 
performed on the comparison programs by mean average error (MAE) and root mean square 
error (RMSE) [32]. The differences between RADBIOMOD and the comparison programs 




TCP and NTCP results for each of the sample cases are shown in Tables 2 and 3, respectively.  
 
There were non-significant differences between RADBIOMOD and XiO for the MP TCP 
model. The TCPs of the five prostate cancer patients had MAE and RMSE values of 0.25% 
and 0.31%, respectively, while the TCPs of the five head and neck cancer patients had MAE 
and RMSE values of 0.06% and 0.06%, respectively. 
 
There were non-significant differences between RADBIOMOD and XiO for the LKB NTCP 
model. The parotid NTCPs of the five head and neck cancer patients had MAE and RMSE 
values of 0.18% and 0.21%, respectively, while the lung NTCPs for the five lung cancer 
patients had MAE and RMSE values of 0.03% and 0.06%, respectively. 
 
There were non-significant differences between RADBIOMOD and CERR for the LKB 
NTCP model. The parotid NTCPs of the five head and neck cancer patients had MAE and 
RMSE values of 0.49% and 0.55%, respectively, while the lung NTCPs for the five lung 
cancer patients had MAE and RMSE values of 0.02% and 0.03%, respectively. 
 
There were no differences between RADBIOMOD and EUDMODEL for both the EUD TCP 
model and the EUD NTCP model. The EUD TCP was tested for five prostate cancer patients 
and five head and neck cancer patients; and the EUD NTCP was tested for the parotids for 
five head and neck cancer patients and the lungs for five lung cancer patients. The results 
were identical, with MAE and RMSE being 0% for all comparisons. 
 
Similarly, there were no differences between RADBIOMOD and TCP_NTCP_CALC for the 
MZM TCP model. The TCP was tested for five prostate cancer patients and five head and 




We have developed a program for using biological models to evaluate radiotherapy treatment 
plans that we have fully described and successfully validated with existing biological 
modelling programs. 
 
Because RADBIOMOD contains features not included in other programs, some of the 
features could not be validated. For example, RADBIOMOD’s MP TCP model includes a β 
parameter, hypoxia, and sensitiser enhancement, none of which are included in XiO, so were 
not tested. 
 
The comparisons between the models tested in XiO and CERR as compared with 
RADBIOMOD indicated that differences were very small, however the numbers were not 
identical. Some of the small variations that arose were likely due to the way the DVH data is 
used by the various programs. XiO and CERR perform calculations using the radiotherapy 
planning data, whereas RADBIOMOD performs calculations using exported DVH tables. 
Differences in DVH binning may be a source of error. In contrast, EUDMODEL and 
TCP_NTCP_CALC produce identical results to RADBIOMOD, probably because they also 
use exported DVH tables and have identical algorithms. The random number generator used 
in the MP TCP model may be a further source of error in that model. 
 
Interestingly, the results varied significantly between the MP TCP model, the MZM TCP 
model, and the EUD TCP model; and also between the LKB NTCP model and the EUD 
NTCP model. This could be due to the fact that the model parameters were selected from a 
number of different sources, and many of them have not been clinically validated. 
 
RADBIOMOD is an extra addition to a range of biological modelling programs that are 
already available, including BIOPLAN [6], TCP_NTCP_CALC [12], CERR [25], 
SABRE [33], and EUDMODEL [22]. Similar to these programs, RADBIOMOD can perform 
calculations using a variety of biological models. However, RADBIOMOD also has several 
features that make it unique. Its strongest feature is the Microsoft Excel environment, which 
should be familiar and therefore easy to learn for most radiation oncologists, radiation 
therapists, and medical physicists. This environment allows easy manipulation of data, 
including situations where the DVH output from the TPS needs to be changed into a format 
that RADBIOMOD recognises. The VBA code can also be easily customised to the user’s 
needs, for example if the user would like to add an extra parameter to any of these models. 
Furthermore, the calculation time is very quick, allowing the rapid evaluation of multiple 
treatment plans. These features make RADBIOMOD ideally suited for research into the 
clinical validation of biological models or planning studies using novel radiotherapy 
techniques [34, 35]. 
 At this stage, RADBIOMOD is purely a research tool, and we do not recommend its use in 
routine clinical practice. Biological modelling in general still has a number of limitations that 
require further improvements before it can be used clinically. For example, a wide range of 
different models and model parameters are available, and all of them give slightly different 
results. Most models and parameters have not been prospectively validated with clinical 
data [3]. Models and parameters published by other groups may have fundamental 
differences that limit their use in the local setting. For instance, differences in treatment 
technique (3D-CRT vs IMRT, different beam angles, etc) or differences in patient 
characteristics (demographics, comorbidities, etc) may limit their generalisability [3]. This 
limitation could potentially be overcome if institutions derived their own biological model 
parameters based on their own experiences [3]. 
 
Despite these current limitations, the potential for biological modelling is immense. It is 
widely recognised that physical parameters for plan evaluation are mere surrogate measures 
of biological responses, and these should be replaced by biological indices in order for the 




RADBIOMOD makes multiple biological models available in a user-friendly and familiar 
format. It produces results that are non-significantly different from existing biological 
modelling calculators for the models tested. It is hoped that this freely available, user-friendly 
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Figure 1. LKB NTCP calculation window 
